COSCIENS ACQUIRES NUALTIS CORP.
TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the acquisition of Nualtis Corp. (“Nualtis”), a Montreal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies, with applications for both human and animal health. The…
Cosciniac has acquired Nualtis Corp., a significant development in the industry. The news release contains "forward-looking statements" that outline the company's expectations and intentions regarding the acquisition. These statements are subject to the "safe harbour" provisions of applicable securities legislation. The release emphasizes that all forward-looking statements are given with caution and may not come to pass.
The acquisition is expected to bring numerous benefits and opportunities, including the growth of Nualtis' product pipeline across various markets, successful completion of regulatory submissions and commercialization activities, and the potential for increased revenue and economic contributions. The timing and nature of commercial product launches are also anticipated to be favorable.
Additionally, the company plans to complete further tranches of an offering, convert and repay debentures, and maintain sufficient liquidity following the completion of the offering. The meeting to receive required approvals, the company's overall financial position, and its future outlook are all crucial factors in this acquisition.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
